Madrigal Pharmaceuticals Plunges 11% — A Billion-Dollar Hit or a Biotech Trap?
Madrigal Pharmaceuticals experienced an 11% stock drop despite significant revenue growth. This episode explores the reasons behind the investor sell-off, including earnings misses, insider share sales, and competitive pressures.